Arimidex with Anavar

trying to recover your natural test and taking anavar are counterproductive. you need to go off anabolics and do a basic pct. just do a search on pct and you will get tons of info. you will not restore natural test levels with anavar and arimidex.

jb

Re: Arimidex with Anavar

Posted by: kaytoo

Would it be safe to use the Arimidex with my current Anavar cycle and, also, can I mix in the occasional ECA cocktail as I'm still trying to shed a few pounds of fat.

Just wanted to add a bit to jb's post since you're new: Anavar shuts down test production, which also means estrogen production since the majority of estrogen in men is created from testosterone, and doesn't convert to or have an affinity for the estrogen receptor. Therefore, estrogen levels are quite low on an anavar cycle, rendering the concomitant use of Arimidex pointless.

ECA w/ var and/or arimidex is fine.

So basically, using the 2 at the same time would be a waste. At least from the Arimidex point of view.

I've also just ordered some Nolvadex XT. Would it be best to use them in an alternating cycle or should I go with mainly the Nolvadex then add some Var exclusively for hard training days ie 2-3 days before.

I'm not so good with OTC supps, so I can't answer your Nolvadex XT questions.

Keep in mind, there is a difference between nolvadex and Nolvadex XT are not the same thing. There might be some people who would think you simply misspelled nolvadex.

Good read here mate, hope it helps gg

nolvadex XT has been removed from the market. Because it contained pharmaceuticals not listed on the label nor available w/o an Rx or from a research company. No wonder it worked.

Here is an interesting study in regard to anavar.

Clin Endocrinol (Oxf). 1993 Apr;38(4):393-8.
The effects of oxandrolone on the growth hormone and gonadal axes in boys with constitutional delay of growth and puberty.
Malhotra A, Poon E, Tse WY, Pringle PJ, Hindmarsh PC, Brook CG.

Endocrine Unit, Middlesex Hospital, London, UK.

OBJECTIVE: We studied the effects of oxandrolone on serum concentrations of LH, FSH, testosterone, GH, SHBG, DHEAS, IGF-I and insulin in boys with constitutional delay of growth and puberty. DESIGN: Ten boys with constitutional delay of growth and puberty, mean age 13.8 years (range 12.4-15.5) were studied. Twenty-four-hour serum concentration profiles of GH, LH and FSH were constructed by drawing blood samples at 20-minute intervals. Three study occasions over a period of 6 months were chosen to assess hormone concentrations before, during and 6 weeks after a 3-month course of oxandrolone (2.5 mg once daily) therapy. RESULTS: Growth velocity increased during oxandrolone treatment and stayed higher after therapy (pre 3.9 +/- 0.5; on 6.3 +/- 0.8; post 6.4 +/- 0.9 cm/year (mean +/- SEM) two way ANOVA, F = 5.3, P = 0.02). Oxandrolone had androgenic effects, suppressing mean serum LH concentrations from 1.7 +/- 0.3 to 1.1 +/- 0.2 U/I and serum Testosterone concentrations from 1.9 +/- 0.6 to 0.8 +/- 0.1 nmol/l. SHBG concentrations were also reduced from 130.9 +/- 14.6 to 30.7 +/- 7.3 nmol/l. Serum GH concentration fell slightly from 5.9 +/- 0.6 to 4.8 +/- 0.5 mU/l. After cessation of treatment, there was a significant 'rebound' in mean 24-hour serum LH (2.6 U/l +/- 0.4) and testosterone concentrations (3.2 +/- 0.9 nmol/l) but no change in serum GH concentrations. SHBG values also rose but not to the same extent as those observed before therapy (82.0 +/- 8.4 nmol/l). There were no statistically significant differences in serum concentrations of FSH, DHEAS, IGF-I and insulin over the study period. In a stepwise multiple regression analysis of factors that might influence the growth rate observed, the 24-hour mean serum testosterone concentration and the treatment (on or off) with oxandrolone were the main influences. The relationship was described by the equation Height velocity = 0.69 (24-hour mean serum testosterone concentration)+1.70 (treatment regimen)+3.37 (adjusted R2 = 0.35, F = 8.39, P = 0.001). CONCLUSIONS: Oxandrolone has an androgenic action as shown by changes in serum LH, testosterone and SHBG concentrations and by the lack of effect on FSH. No effect of oxandrolone on the GH axis was documented. We suggest that the growth promoting effects of oxandrolone are related in part to the mild androgenic effects of the steroid and the growth acceleration following oxandrolone withdrawal may reflect increasing total serum testosterone concentrations and decreasing levels of SHBG and progress in puberty.

PMID: 8319371 [PubMed - indexed for MEDLINE]

Hey LI, one thing stood out to be in the study: the lack of change in FSH. I wonder why...

Posted by: ready2explode

Hey LI, one thing stood out to be in the study: the lack of change in FSH. I wonder why...

I read some articles that anavar suppresses but does not shut down the HTPA. I didn't find any studies to substantiate that though. I have no idea as to why FHS is unaffected.

in this study with HIV men anavar did demonstrate reductions in fsh;

=========

J Acquir Immune Defic Syndr. 2006 Mar;41(3):304-14.

Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study.
Grunfeld C, Kotler DP, Dobs A, Glesby M, Bhasin S.

University of California-San Francisco, and Department of Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA. [email protected]

Abstract
OBJECTIVE: To evaluate the efficacy and safety of oxandrolone in promoting body weight and body cell mass (BCM) gain in HIV-associated weight loss.

METHODS: Randomized, double-blind, placebo-controlled trial. Two hundred sixty-two HIV-infected men with documented 10% to 20% weight loss or body mass index < or =20 kg/m were randomized to placebo or to 20, 40, or 80 mg of oxandrolone daily. After 12 weeks, subjects were allowed to receive open-label oxandrolone at a dose of 20 mg for another 12 weeks.

RESULTS: Body weight increased in all groups, including the group receiving placebo, during the double-blind phase (1.1 +/- 2.7, 1.8 +/- 3.9, 2.8 +/- 3.3, and 2.3 +/- 2.9 kg in placebo and 20-, 40-, and 80-mg oxandrolone groups, respectively; all P < 0.014 vs. baseline). BCM increased from baseline in all groups (0.45 +/- 1.7, 0.91 +/- 2.2, 1.5 +/- 2.5, and 1.8 +/- 1.8 kg in placebo and 20-, 40-, and 80-mg oxandrolone groups, respectively). At 12 weeks, only the gain in weight at the 40-mg dose of oxandrolone and the gain in BCM at the 40- and 80-mg doses of oxandrolone were greater than those in the placebo group, however. Oxandrolone treatment was associated with significant suppression of sex hormone-binding globulin, luteinizing hormone, follicle-stimulating hormone, and total and free testosterone levels. Treatment was generally well tolerated but accompanied by significant increases in transaminases and low-density lipoprotein as well as decreases in high-density lipoprotein.